ANZUP Strategy 2025-2028
Click Here to Read
Major Improvement in Advanced Prostate Cancer Treatment!
New findings from the ENZA-p study show a world-first treatment combination that significantly improves survival and quality of life for people with advanced prostate cancer (mCRPC)
Read more here
Groundbreaking three year partnership
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year research partnership aimed at accelerating clinical trials and advancements in prostate cancer treatment.
Read more here
Every meaningful advance in treatment has been the result of a clinical trial
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group mission is to improve treatments and outcomes for people affected by Below the Belt cancers.
Find out more
Poor outcomes from advanced prostate cancer can be reversed with targeted treatment
New research findings of the ENZAMET (ANZUP 1304) study, reveal that people who inherit a genetic biomarker known to predict poorer outcomes with routine prostate cancer treatment, can be successfully treated and have better survival outcomes with personalised hormonal therapy for advanced prostate cancer.
Find Out More
LuPSMA shows promise as first-line treatment for prostate cancer
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic prostate cancers who have exhausted all other treatment options. The UpFrontPSMA (ANZUP 1904) study was the first to test this treatment in patients with newly diagnosed prostate cancers that had spread.
Find Out More
View Online
ANZUP x Sydney Sock Project
That’s right, we have partnered up with the Sydney Sock Project to design and produce a variety of cheeky socks. Say hello to the ‘Penis Sock’ ‘Testicle Sock’ and ‘Below the Belt Sock’.
Grab a Pair
Previous slide
Next slide
Donate to
improve lives!
Your Gift
Your Details
Your Payment

xx Gift of $xx

Go back
Go back

Or enter your own donation amount

0
Trials
0 +

Sites

0 +

Patients Enrolled

0

Countries

ANZUP Cancer, ANZUP

What we do

ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.

ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
Read More
ANZUP Cancer, ANZUP

Join ANZUP

If you are not yet an ANZUP member then join our large multidisciplinary network of urogenital and prostate cancer researchers, clinicians, nurses, psychologists, scientists, allied health and consumer representatives. Membership is free.
If you are a member of the community and would like to learn more about below the belt cancers, then join ‘Friends of ANZUP’.
Read More
ANZUP Cancer, ANZUP

Trials and Research

All of the major milestones in controlling cancer worldwide have come through clinical trials, but we still have a long way to go to help every person affected, at risk or diagnosed with this disease.

We have clinical trials across each cancer type, in various stages of progress: in activation, open to patient recruitment, in follow up and completed trials.
Read More

Telehealth and Teletrials

Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations.

Read More

Teleheath and Teletrials

Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.

Read More

ANZUP Follow

The Australian and New Zealand Urogenital and Prostate cancer trials group aims to develop, foster and promote prostate and other urogenital cancer research

ANZUPtrials
anzuptrials ANZUP @anzuptrials ·
16 Feb

It’s a wrap @ASCO #GU25! Our final @ANZUPTrials poster #SUBDUE3 #BladderCancer study presented by @KevinKeane. Study led by Prof Dickon Hayne and supported by #SouthMetropolitanHealthService @uwanews @CancerAustralia @Prof_IanD

Reply on Twitter 1891041038485037195 Retweet on Twitter 1891041038485037195 6 Like on Twitter 1891041038485037195 19 Twitter 1891041038485037195
Retweet on Twitter ANZUP Retweeted
drmhofman Michael Hofman @drmhofman ·
16 Feb

PSMA PET/CT or radioligand therapy mentioned 600 times in the @ASCO #GU25 prostate cancer abstracts (advanced and localized). I think around 1 in 5 of abstracts contain PSMA !! Amazing to see the uptake of this new technology over the last 10 years.

ENZA-P was my highlight from…

Reply on Twitter 1890925820715089971 Retweet on Twitter 1890925820715089971 19 Like on Twitter 1890925820715089971 80 Twitter 1890925820715089971
anzuptrials ANZUP @anzuptrials ·
16 Feb

Great to see @ANZUPtrials #ENZAp study feature in the @australian Congrats to all involved! @drlouiseemmett @MovemberAUS @CancerAustralia @AstellasEurope #ARTnet @StVincentClinic @RoyMorganAus @Novartis @mimsoftware @GenesisCare @ANSTO @TrialsCentre @Prof_IanD

The Australian @australian

Scientists ‘excited’ by promising trial results showing men with aggressive prostate cancer felt better and lived longer when taking a combined therapy: https://tinyurl.com/yxhvp3p9

Reply on Twitter 1890964931798831136 Retweet on Twitter 1890964931798831136 5 Like on Twitter 1890964931798831136 10 Twitter 1890964931798831136
anzuptrials ANZUP @anzuptrials ·
16 Feb

Great to see @ANZUPTrials #P3BEP poster at @ASCO #GU25 presented by @MartinStockler pictured with #CancerResearch pioneer #LarryEinhorn. Congrats to A/Prof Peter Grimison & the #P3BEP team for this important #GermCellCancer research @CR_UK @CUH_NHS #ANZCHOG @COGorg @TrialsCentre

Reply on Twitter 1890937591261737364 Retweet on Twitter 1890937591261737364 6 Like on Twitter 1890937591261737364 20 Twitter 1890937591261737364
Load More

Latest News